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Abstract: Present work employs the QSAR formalism to predict the ED50 anticonvulsant 
activity of ringed-enaminones, in order to apply these relationships for the prediction of 
unknown open-chain compounds containing the same types of functional groups in their 
molecular structure. Two different modeling approaches are applied with the purpose of 
comparing the consistency of our results: (a) the search of molecular descriptors via 
multivariable linear regressions; and (b) the calculation of flexible descriptors with the 
CORAL (CORrelation And Logic) program. Among the results found, we propose some 
potent candidate open-chain enaminones having ED50 values lower than 10 mg·kg−1 for 
corresponding pharmacological studies. These compounds are classified as Class 1 and 
Class 2 according to the Anticonvulsant Selection Project.  
Keywords: QSAR theory; anticonvulsant activity; open-chain enaminone;  
flexible descriptors 
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1. Introduction  
Enaminones are a group of organic compounds carrying the conjugated system N–C=C–C=O [1]. 
The literature reports information about the chemistry of enaminones, their physicochemical properties 
and biological activities [2–10]. In spite of the interest in these compounds, only a limited number of 
theoretical works have been published on the prototype enaminone 2-propenal-3-amine based on the 
semiempirical molecular orbitals theory [11,12] and the quantum chemical study using ab initio 
method or the density functional theory [13–15].  
Biologically active enaminones may be classified in two different types, according to the layout of 
the functional group [13–15]: (a) open-chain enaminones (OCEs), where the characteristic group is 
part of a chain (thus having the flexibility that enables different conformers); and (b) ringed enaminones 
(REs), where the characteristic group is part of a ring and the enaminone group is not flexible. In 
recent years, a group of REs has been reported as anticonvulsant. The mechanism of action of these 
biomolecules would be similar to many classic antiepileptics and second-generation drugs, while they 
act on ion channels by blocking the passage of ions through them [2–10]. Among the bioactive REs 
appears DM5 (methyl 4-(4-chlorophenylamino), 6-methyl,2-oxocyclohex-3-ene carboxylate),  
(Figure 1a) and ON2 (ethyl 6-methyl,4-(5-methylisoxazol-3-ylamino), 2-oxocyclohex-3-ene carboxylate), 
(Figure 1b) [6,7]. Another family of enaminones with biological activity is derived from benzylamine 
enaminones, (Figure 1c) [9]. These have anticonvulsant activity similar to DM5 (aniline enaminone 
derivate) and ON2 (isoxasol enaminone derivate).  
Figure 1. (a) Aniline enaminone derivative DM5. (b) Isoxasol enaminone derivative ON2. 
(c) Benzylamine enaminone derivative. 
 
Distance between the carbonyl oxygen and the aromatic ring is of great importance during the 
binding of the molecule with the sodium channel [16]. Conformations that adopt a RE influence this 
distance may result in different activities [2–9]. In a previous study, we have performed a QSAR study 
on the activity of various RE in the active conformation [17].  
Now, a comparison between both enaminone families demonstrates the similarity of the molecular 
structure and functional groups involved in the linkage with the sodium channel, as evidenced by the 
different pharmacophore models reported in the literature [16,18–20] (Figure 2). In this way, an OCE 
could bind to the receptor in a similar way as the REs do. Moreover for the OCE, the flexible open 
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chain and greater ability to transport through biological membranes would allow more precise fitting 
of its site of action.  
Figure 2. Pharmacophore models reported in the literature and ringed and open-chain 
enaminones structures. 
 
Accordingly, it is feasible to formulate the following question: could an open-chain enaminone have 
anticonvulsant activity as it is the case for ringed enaminones? Several techniques have been 
developed to elucidate a relationship between the structure and biological activity, SAR, QSAR [21], 
S-SAR [22–24]. The main objective of this work is to study a molecular set of OCEs for predicting 
their antiepileptic activity using the QSAR methodology, which would allow us to provide some 
guidelines on the anticonvulsant properties of this class of molecules.  
2. Materials and Methods 
2.1. Experimental Data  
The experimental information on the antiepileptic activities of the molecular structures is obtained 
from various recent publications, by methods that have been previously reported [4–10]. Due to the 
scarcity of experimental information and the need for QSAR models, it is necessary to collect data 
from different authors [4–10]. However, we pay attention that the parameter of activity (ED50), which 
represents the dose at which 50% of individuals reach the desired effect, is obtained by using the same 
assay. This is determined in the “Anticonvulsant Selection Project” (ASP) by the experimental method 
“Maximal electroshock seizure” (MES) [2,7,8,25]. For modeling purposes, we use Log10 ED50 to get a 
more standardized property.  
2.2. Geometry Optimization and Molecular Descriptors Calculation 
The structures of all the examined compounds are optimized with the Semiempirical Method PM3 
(Parametric Method-3) included in the HyperChem 6.03 software [26]. By means of the software 
Dragon [27], we calculate a set of 1307 molecular descriptors [28], which includes. 0D: Constitutional 
Descriptors, 1D: Functional Groups, Empirics Descriptors, Atom Centred Fragments; 2D: Descriptors 
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topological, Molecular walk counts, Galvez Charge Index, BCUT Descriptors; 3D: Descriptors of 
Charge, aromatic index, molecular profiles of Randic, Geometry Descriptors, RDF Descriptors,  
3D-Morse Descriptors, WHIM descriptors and GATEWAY Descriptors. In addition, 5 descriptors 
obtained from the semiempirical calculation are added (molecular dipole moment, energy of the HOMO 
and LUMO and HOMO-LUMO gap). Therefore, the set of descriptors contains D = 1312 variables.  
2.3. Model Development 
The QSAR established in this work are obtained via two different modeling approaches with the 
purpose of comparing the consistency of our results: (a) the search of molecular descriptors via 
multivariable linear regressions; and (b) the calculation of flexible descriptors with the CORAL 
(CORrelation And Logic) program.  
2.3.1. Linear Descriptors Search 
In the search for the best model we use the Matlab 7.0 [29]. Our quest is to find from the set of D 
descriptors a subset of d ones (d <<< D) with the minimum standard deviation (S), so we use the 
Replacement Method (RM) [30–32]. Standard deviation is defined as follows: 
1
21      
( 1)
N
i
i
S res
N d 
     (1) 
where N is the number of molecules in the calibration set CC (molecular set used for calibration of the 
model), resi is the residue of the molecule i (difference between experimental and predicted property of i).  
The QSAR Theory searches for the best predictions of the activity, but it is a rule in practice that the 
models should be simple, interpretable, and have a descriptor per six or seven molecules in order to 
achieve satisfactory results [33]. Then, we calculate the maximum number of descriptors (dnm) to be 
included in the linear regression equation as:  
nm 7
Nd   (2) 
On the other hand, the Kubinyi function FIT [34,35] is used to get the optimum number of 
descriptors (dopt) of each linear regression established. The FIT criterion is a very effective method for 
obtaining the optimal number of descriptors of a particular model [32–34].  
2.3.2. Calculation of Flexible Descriptors 
CHEMPREDICT/CORAL (CORrelation And Logic) version 1.4 [36] is a freeware for Windows. 
Each molecular structure must be represented by SMILES (Simplified Molecular Input Line Entry 
System) notation, calculated with ACD/ChemSketch software [37]. CORAL approach is based on the 
presence of certain SMILES attributes occurring in the molecule which can be associated to the 
activity of the molecule under evaluation [38–41]. As SMILES attributes are used the symbols 
representing the chemical elements, cycles, branching of molecular skeleton, charges, etc. More 
specific details on the CORAL algorithm can be found in the recent literature [38–41]. 
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2.3.3. Model Validation 
A next step of current analysis is to verify the validation (predictive capability) of the QSAR 
relationships established on a calibration set of chemical structures. These must be predictive and 
capable to adapt equally-well on new structures (test set) that do not participate during the training of 
the model. We choose the well-known leave-one-out (loo) and leave-more-out (l-%-o) cross-validation 
procedures, where % represents the percentage of molecules removed from the calibration set.  
For l-%-o, we generate 1,000,000 cases of random molecules removal, where % = 10 (five compounds). 
The standard deviations Stest and Sl-%-o are calculated in this step.  
3. Results and Discussion 
3.1. QSAR on Ringed-Enaminones 
In a previous work we have developed a mathematical model for the prediction of ED50 in REs 
compounds [17]. This model contains five molecular descriptors and involves a calibration set of  
46 compounds. For such model (Equation 3), validation is performed with a set of five molecules, 
leading to Stest = 0.232 and Rtest = 0.835: 
     
     
10 50log 3.3102 0.579 3.7124 0, 737 6 2.3384 0.387 8
0.1282 0.017 025 0.66732 0.118 15 33.683. 5.16 4
ED BELe BELp
RDF v Mor e R e
       
       
(3) 
N = 46; p < 10−4; Rcal = 0.870; Scal = 0.206; Rtest = 0.835; Stest = 0.232; Rloo = 0,925;  
Sloo = 0.198; Rl-10-o = 0.712; Sl-10-o = 0.319 
In this study, we propose a new five-descriptor model (Equation 4). The calibration is established 
with 51 compounds, including all compounds belonging to Equation 3. Thus, Equation 4 contains 
more biochemical information and its predictive power may be higher. This last model is applied to the 
same calibration and test sets of Equation 3, leading to:  
LumoHomoEeRmRDF
mRDFClOGED

 

)076.0(402.04)793.4(631.35115)044.0(238.0
025)014.0(0072.0)...()005.0(024.0)867.0(247.2log 5010
 (4) 
N = 51; p < 10−4; Rcal = 0.864; Scal = 0.209; Rtest = 0.947; Stest = 0.204; Rloo = 0.847;  
Sloo = 0.228; Rl-%-o = 0.746; Sl-%-o = 0.343 
In Equation 3, BELe6 and BELp8 are BCUT descriptors, RDF025v is a Radial Distribution Function 
descriptor, Mor15e is a 3D-MoRSE descriptor and R4e+ is a 3D GATEWAY descriptor. The structural 
variables appearing in Equation 4 combine multidimensional aspects of the molecular structure and are 
classified as follows: Radial Distribution Function descriptors (RDF025m and RDF115m), Geometrical 
(G(O..Cl)), GATEWAY (R4e+) and HOMO-LUMO energy gap (Homo-Lumo). A brief explanation of 
the descriptors participating in both equations is provided in Table 1.  
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Table 1. Symbols and description for molecular descriptors involved in QSAR. 
Descriptor Type Details 
BELe6 
BCUT 
Lowest eigenvalue n. 6 of Burden matrix/weighted by atomic 
Sanderson electronegativities 
BELp8 
Lowest eigenvalue n. 8 of Burden matrix/weighted by atomic 
polarizabilities 
RDF025v Radial 
Distribution 
Function 
Radial Distribution Function—2.5/weighted by atomic van der 
Waals volumes 
RDF025m Radial Distribution Function—2.5/weighted by atomic masses 
RDF115m Radial Distribution Function—11.5/weighted by atomic masses
Mor15e 3D-MoRSE 
3D-MoRSE—signal 15/weighted by atomic Sanderson 
electronegativities 
R4e+ GETAWAY 
R maximal autocorrelation of lag 4/weighted by atomic 
Sanderson electronegativities 
G(O..Cl) Geometrical Sum of geometrical distances between O..Cl 
Homo-Lumo 
Quantum 
Chemical 
HOMO-LUMO energy gap 
The highest intercorrelation coefficient for the five descriptors of Equation 3 is 0.733. This is 
because BELe6 and BELp8 descriptors belong to the same BCUT family. In general, QSAR models 
accept intercorrelations up to the value 0.98, but the orthogonalization process can be used to give better 
analysis when necessary [42,43]. Equation 4 has low intercorrelations between descriptors, the highest 
value is 0.561. Only descriptor R4e+ (R maximal autocorrelation of lag 4/weighted by atomic 
Sanderson Electronegativities) simultaneously appears in both equations and has low intercorrelations 
to the remaining ones.  
Table 2 lists the compounds of both models, together with the experimental and predicted ED50 
values. Figure 3 shows the experimental and predicted Log10 ED50 plot for the calibration and 
validation sets. From this figure it can be noted that the two enaminones of the validation set, 47 and 
51, are very well predicted. Dispersion plots of the residuals for the calibration and test sets are 
provided in the supplementary material. Such figures reveal that the behavior of the residuals in terms 
of the predictions follows a random distribution, in accordance to the assumption involved in linear 
regression analysis. No molecule in the set exhibits a residual larger than the value of S. 
Table 2. Experimental and predicted Log10 ED50 antiepileptic activity values of the 
compounds of calibration set and test set. 
No. Chemical name ED50 
(mg·Kg−1)
Exp.
Equation 
3 
Equation 
4 
Equation 
5 
1 
Ethyl 6-methyl-4-(5-methylisoxazol-3-
ylamino)-2-oxocyclohex-3-enecarboxylate 
68.39 [4] 1.835 1.815 1.831 1.813 
2 
Methyl 4-(4-cyanophenylamino)-6-methyl-
2-oxocyclohex-3-enecarboxylate 
248.31 [4] 2.395 2.229 2.252 2.226 
3 
Methyl 4-(4-chlorophenylamino)-6-methyl-
2-oxocyclohex-3-enecarboxylate 
26.18 [4] 1.418 1.509 1.466 1.517 
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Table 2. Cont. 
4 2-acetamido-N-benzylpropanamide 76.38 [5] 1.883 1.716 1.677 1.634
5 2-acetamido-N-(3-fluorobenzyl)propanamide 77.27 [5] 1.888 1.945 1.791 1.994
6 
2-acetamido-N-(2-fluorobenzyl)-2-(furan-2-
yl)acetamide 
39.99 [5] 1.602 1.215 1.294 1.315
7 
2-acetamido-N-(3-fluorobenzyl)-2-(furan-2-
yl)acetamide 
13.27 [5] 1.123 1.132 1.291 1.315
8 
2-acetamido-N-(4-fluorobenzyl)-2-(furan-2-
yl)acetamide 
12.68 [5] 1.103 1.302 1.228 1.315
9 
2-acetamido-N-(2,5-difluorobenzyl)-2-(furan-2-
yl)acetamida 
23.77 [5] 1.376 1.577 1.522 1.448
10 
2-acetamido-N-(2,6-difluorobenzyl)-2-(furan-2-
yl)acetamide 
62.95 [5] 1.799 1.604 1.631 1.687
11 2-acetamido-N-benzylpent-4-enamide 33.57 [5] 1.526 1.653 1.605 1.533
12 
2-acetamido-N-benzyl-2-(tetrahydrofuran-2-
yl)acetamide 
51.64 [5] 1.713 1.770 1.272 1.746
13 2-acetamido-N-benzyl-2-(furan-2-yl)acetamide 10.28 [5] 1.012 1.383 1.252 1.182
14 
2-acetamido-N-benzyl-2-(5-methylfuran-2-
yl)acetamide 
19.19 [5] 1.283 1.450 1.200 1.282
15 
2-acetamido-N-benzyl-2-(1H-pyrrol-2-
yl)acetamide 
16.07 [5] 1.206 1.486 1.299 1.315
16 
2-acetamido-N-benzyl-2-(5-methyl-1H-pyrrol-
2-yl)acetamide 
36.48 [5] 1.562 1.530 1.376 1.415
17 
2-acetamido-N-benzyl-2-(thiophen-2-
yl)acetamide 
44.77 [5] 1.651 1.388 1.628 1.593
18 
2-acetamido-N-benzyl-2-(thiophen-3-
yl)acetamida 
87.70 [5] 1.943 1.783 1.770 1.979
19 
2-acetamido-N-benzyl-2-(1H-pyrrol-1-
yl)acetamide 
80.17 [5] 1.904 1.572 1.538 1.399
20 
2-acetamido-N-benzyl-2-(1H-pyrazol-1-
yl)acetamide 
16.48 [5] 1.217 1.249 1.294 1.325
21 
2-acetamido-N-benzyl-2-(pyridin-2-
yl)acetamide 
10.79 [5] 1.033 0.880 1.037 1.195
22 
2-acetamido-3-amino-N-benzyl-3-
thioxopropanamide 
86.50 [5] 1.937 1.550 1.921 1.981
23 
2-acetamido-N-benzyl-2-
(ethylamino)acetamide 
42.36 [5] 1.627 1.525 1.635 1.679
24 
2-acetamido-N-benzyl-2-
(hydroxy(methyl)amino)acetamide 
29.99 [5] 1.477 1.465 1.215 1.712
25 
2-acetamido-N-benzyl-2-(1-
phenylhydrazinyl)acetamide 
42.76 [5] 1.631 1.524 1.663 1.811
26 2-acetamido-N-benzyl-2-ethoxyacetamide 61.94 [5] 1.792 1.795 1.922 1.368
27 2-acetamido-N-benzyl-3-methoxypropanamide 8.30 [5] 0.919 0.954 1.135 1.201
28 2-acetamido-N-benzyl-3-ethoxypropanamide 16.98 [5] 1.230 1.232 1.385 1.197
29 
2-acetamido-N-benzyl-2-(pyrazin-2-
yl)acetamide 
14.79 [5] 1.170 0.929 1.015 0.893
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Table 2. Cont. 
30 
2-acetamido-N-benzyl-2-(pyrimidin-2-
yl)acetamida 
8.09 [5] 0.908 1.151 1.344 1.121
31 2-acetamido-N-benzyl-2-(oxazol-5-yl)acetamide 10.50 [5] 1.021 0.998 1.149 0.88 
32 2-acetamido-N-benzyl-2-(thiazol-5-yl)acetamide 11.99 [5] 1.079 1.417 1.717 1.291
33 
2-acetamido-2-(3-aminophenylamino)-N-
benzylacetamide 
98.40 [5] 1.993 2.102 2.023 1.85 
34 2-acetamido-N-benzyl-2-(furan-2-yl)acetamide 18.37 [5] 1.264 1.396 1.255 1.182
35 
Ethyl 4-(4-chlorophenylamino)-6-methyl-2-oxo-
3-cyclohexene-1-carboxylate 
16.67 [7] 1.222 1.085 1.184 1.124
36 
Ethyl 4-(4-bromophenylamino)-6-methyl-2-oxo-
3-cyclohexene-1-carboxylate 
7.89 [7] 0.897 1.259 0.861 1.383
37 
Ethyl 6-methyl-2-oxo-4-(4-
(trifluoromethoxy)phenylamino)cyclohex-3-
enecarboxylate 
37.07 [7] 1.569 1.708 1.831 1.553
38 
Ethyl 4-(4-cianophenylamino)-6-methyl-2-oxo-
3-cyclohexene-1-carboxylate 
63.10 [7] 1.800 1.852 1.847 1.595
39 
3-(4-chlorophenylamino)-5-methyl-2-
cyclohexenone 
40.36 [7] 1.606 1.804 1.570 1.576
40 
3-(4-iodophenylamino)-5-methyl-2-
cyclohexenone 
76.91 [7] 1.886 1.924 1.829 1.835
41 
Methyl 6-methyl-4-(5-methylisoxazol-3-
ylamino)-2-oxocyclohex-3-cyclohexene-1-
carboxylate 
149.28 [8] 2.174 1.867 2.001 2.087
42 
Tert-butyl 6-methyl-4-(5-methylisoxazol-3-
ylamino)-2-oxocyclohex-3-cyclohexene-1-
carboxylate 
119.67 [8] 2.078 1.974 1.861 2.181
43 
Methyl 4-(benzylamino)-6-methyl-2-
oxocyclohex-3-cyclohexene-1-carboxylate 
64.57 [9] 1.810 2.005 2.062 2.019
44 
Methyl 4-(4-fluorobenzylamino)-6-methyl-2-
oxocyclohex-3-cyclohexene-1-carboxylate 
158.85 [9] 2.201 2.030 2.164 2.118
45 
3-(benzylamino)-5,5-dimethylcyclohex-2-
cyclohexenone 
52.97 [9] 1.724 1.633 1.678 1.892
46 
Methyl 4-(benzylamino)-6,6-dimethyl-2-
oxocyclohex-3-enecarboxylate 
131.83 
[10] 
2.120 2.219 2.107 1.904
47 * 
Methyl 6-methyl-4-(4-nitrophenylamino)-2-
oxocyclohex-3-enecarboxylate 
299.92 [4] 2.477 2.441 2.793 2.599
48 * 2-acetamido-N-benzyl-2-phenylacetamide 20.28 [7] 1.307 1.505 1.347 1.269
49 * 
2-acetamido-N-benzyl-2-
(dimethylamino)acetamide 
45.29 [7] 1.656 1.413 1.540 1.804
50 * 
2-acetamido-2-(furan-2-yl)-N-(pyridin-3-
ylmethyl)acetamide 
29.99 [7] 1.477 1.396 1.255 1.182
51 * 5,5-dimethyl-3-(phenylamino)cyclohex-2-enone
109.14 
[10] 
2.038 1.812 1.990 1.434
* Molecules of test set. 
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Figure 3. Experimental and predicted Log10 ED50 plot. ○ Calibration set ● test set  
▲ Enaminones of test set. 
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Now, it is feasible to improve the statistical performance of Equations 3 and 4 by using models 
established via flexible descriptor definitions calculated with the CORAL program. We run a Monte 
Carlo simulation for obtaining the DCW3 descriptor of Equation 5, achieving the following  
QSAR model: 
3
5010 )0008.0(069.0)0227.0(1906.0 DCWEDLog   (5)
N = 46; p < 10−4; Rcal = 0.7627; Scal = 0.192; Rloo = 0.6998; Sloo = 0.350 
The specification of the numerical parameters used in the CORAL calculation is: number of epochs: 
40, number of probes: 5, range of threshold values: 0–2, Dstart = 0.1, dprecision = 0.001, dRweight = 0, 
dCweight = 0, threshold range = 0–5, and α = β = 0.  
Figure 4 plots the predicted activities as function of the experimental data. The predictions achieved 
by model 5 are included in Table 2. 
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Figure 4. Experimental and predicted Log10 ED50 plot using flexible descriptors model:  
○ Calibration set ● test set. 
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It is easily appreciated from the statistical parameters of calibration and leave-one-out validation 
that the quality of Equations 3 and 4 outperforms that of Equation 5. However, we decide to include 
Equation 5 in order to compare the predictions.  
Another crucial problem to consider is the definition of the Applicability Domain (AD) of a QSAR 
model [44–46]. In other words, not even a robust, significant, and validated QSAR model can be 
expected to reliably predict the modeled property for the entire universe of molecules. In fact, only the 
predictions for molecules falling within this AD can be considered reliable and not just model 
extrapolations. The AD is a theoretical region in chemical space, and depends upon the set of chemical 
structures and the experimental property analyzed; hence the AD is different for each QSAR model 
established. We define the AD for each QSAR in terms of the ranges of variation of the numerical 
values of its descriptors: a molecular structure would be, in principle, reliably predicted if its numerical 
descriptor values fall within such ranges. Thus, for Equation (3) BELe6: [0.7180–1.0260], BELp8: 
[0.4540–1.0870], RDF025v: [12.2150–22.5420], Mor15e: [−0.6920–27.8150], R4e+: [0.0330–0.0710]; 
for Equation (4) G(O...Cl): [0.0000–32.1200], RDF025m: [13.9580–24.1070], RDF115m:  
[0.0000–4.8410], R4e+: [0.0330–0.0710], EHomo-Lumo: [−9.8192–(−7.8810)]; for Equation (5) DCW3: 
[15.5091–40.4327]. In addition, the predicted activity for a considered structure based on a given 
combination of descriptors should fall inside (or close to) the range of the experimental activity 
variation, which in the present case is Log10 ED50: [0.8970–2.4770]. 
3.2. QSAR on Open-Chain Enaminones 
The selected OCEs are structurally-related to the REs used in the calibration and validation sets. For 
this selection, an analysis of molecular modulation is carried out, based on an active molecule. Then, 
the molecules 1A, 1B, 1C and 1D are obtained from molecules 3, 51, 43 and 41 (Figure 5). This figure 
shows the conformers of the OCEs. Molecules 3 and 51 belong to the family of aniline derivatives, 43 
pertains to the family of benzylamine derivatives and 41 belongs to the family of isoxasol derivatives.  
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Figure 5. Structure of the 16 conformers of open-chain enaminones. Scheme for the 
selection of the compounds. 
 
The structural similarity between the molecules used in the models and the OCEs suggests that the 
models developed in this work would serve to predict ED50 of these molecules. Having no experimental 
values, a way to verify the predictions is to note that Equations 3 and 4 do not lead to absurd 
predictions (different predictions for the same molecules). As shown in Table 3, the predictions are 
similar for both models. Both equations predict that 1B is the most active, while the enaminone with 
lower activity is 3A. Then, we argue that the predictions obtained are not at random, and that the 
predicted values of ED50 obtained with both models should be close to the experimental observations. 
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Table 3. Log10 ED50 for open-chain enaminones predicted by Equations 3 and 4. 
Molecule Equation 3 Equation 4 PSA a 
1A 2.051 2.041 2 
2A 2.426 2.093 2 
3A 2.456 2.229 2 
4A 2.323 2.037 2 
1B 0.956 0.245 1 
2B 1.529 0.903 1 
3B 1.103 0.667 1 
4B 1.393 0.758 1 
1C 1.329 1.241 1 
2C 1.462 1.556 1 
3C 1.794 1.446 1 
4C 1.505 1.177 1 
1D 1.295 1.416 1 
2D 1.583 1.375 1 
3D 2.172 1.980 b
4D 1.291 1.183 1 
a Anticonvulsant Screening Project (ASP) (21). Class 1: anticonvulsant activity at 100 mg·kg−1 or 
less; Class 2: anticonvulsant activity at doses greater than 100 mg·kg−1; Class 3: inactive at doses of  
300 mg·kg−1. b Equation 4: Class 2; Equation 5: Class 1 (95 mg·kg−1). 
4. Conclusions  
A linear QSAR model is developed to predict ED50 in REs and applied for the prediction of OCEs. 
In addition, an alternative linear model using a different methodology based on the flexible descriptor 
definition is obtained with the same purpose. The developed models allow the prediction of 
antiepileptic activities of 16 OCEs. These compounds are presented as candidate structures for 
corresponding pharmacological studies. The 16 enaminones would be classified as Class 1 and Class 2 
according to ASP. Several of the ED50 obtained here are less than 10 mg·kg−1. Accordingly, 
conformational flexibility in OCEs is a crucial factor to be considered during the study of the 
antiepileptic activity behaviour. 
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